Risperidone Treatment of Sleep Disturbances in Tourette’s Syndrome

Arana-Lechuga, Yoaly; Sánchez-Escandón, Óscar; Santiago-Treviño, Nancy de; Castillo-Montoya, Carlos; Terán-Pérez, Guadalupe; Velázquez‐Moctezuma, Javier

doi:10.1176/jnp.2008.20.3.375

Cited by 9 publications

(3 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is in accordance with the potential of risperidone to manage pediatric aggression in other disorders [177]. Moreover, positive effects of risperidone not only on tics but also on sleep disturbances have been reported in the case of a 12-year-old boy with no previous psychopharmacological treatment [7].…”

Section: Antipsychotic Agentssupporting

confidence: 79%

Tics bei Kindern und Jugendlichen

Menke¹,

Wenzel-Seifert²,

Babl³

et al. 2012

NeuroTransmitter

View full text Add to dashboard Cite

To develop a European guideline on pharmacologic treatment of Tourette syndrome (TS) the available literature was thoroughly screened and extensively discussed by a working group of the European Society for the Study of Tourette syndrome (ESSTS). Although there are many more studies on pharmacotherapy of TS than on behavioral treatment options, only a limited number of studies meets rigorous quality criteria. Therefore, we have devised a two-stage approach. First, we present the highest level of evidence by reporting the findings of existing Cochrane reviews in this field. Subsequently, we provide the first comprehensive overview of all reports on pharmacological treatment options for TS through a MEDLINE, PubMed, and EMBASE search for all studies that document the effect of pharmacological treatment of TS and other tic disorders between 1970 and November 2010. We present a summary of the current consensus on pharmacological treatment options for TS in Europe to guide the clinician in daily practice. This summary is, however, rather a status quo of a clinically helpful but merely low evidence Members of the ESSTS Guidelines Group are listed in Appendix.

show abstract

Section: Antipsychotic Agentssupporting

confidence: 79%

Tics bei Kindern und Jugendlichen

Menke¹,

Wenzel-Seifert²,

Babl³

et al. 2012

NeuroTransmitter

View full text Add to dashboard Cite

show abstract

“…Atypical antipsychotics have been used for their antidopaminergic activity and potential benefit in both symptoms of Tourette and sleep complaints. A single case report of a 12 year old treated with risperidone showed benefit in sleep latency and sleep efficiency [ 42 ]. Most recently aripiprazole has shown some promising results [ 43 ].…”

Section: Treatment Optionsmentioning

confidence: 99%

Tourette disorder and sleep

Blaty

DelRosso

2022

Biomedical Journal

View full text Add to dashboard Cite

“…Up until 2012, several RCTs, ,,− case reports, − open-label studies, − and retrospective studies, − including small groups of patients across different ages, have proven risperidone to be effective in the treatment of tics. Between 2012 and 2017, six systematic reviews/meta-analyses ,,,,, including trials and one case study on risperidone in the treatment of tics have been published.…”

Section: Systematic Review Of Dopamine Receptor Antagonists For the T...mentioning

confidence: 99%

Update on the Pharmacological Treatment of Tics with Dopamine-Modulating Agents

Mogwitz

Buse

Wolff

et al. 2018

ACS Chem. Neurosci.

View full text Add to dashboard Cite

More than 40 years of research and clinical practice have proven the effectiveness of dopamine receptor antagonists in the pharmacological treatment of tics. A blockade of the striatal dopamine-D2 receptors is mainly responsible for their tic-reducing effect. A broad spectrum of dopamine-modulating agents, such as typical and atypical antipsychotics, but also dopamine receptor agonists are used with an immanent discord between experts about which of them should be considered as first choice. The present Review outlines the state of the art on pharmacological treatment of tics with dopamine-modulating agents by giving an systematic overview of studies on their effectiveness and a critical discussion of their specific adverse effects. It is considered as an update of a previous review of our research group published in 2013. The Review closes with a description of the current resulting treatment recommendations including the results of a first published revised survey on European expert's prescription preferences. Based on the enormously growing evidence on its effectiveness and safety, aripiprazole currently seems to be the most promising agent in the pharmacological treatment of tics. Furthermore, benzamides (especially tiapride), which are commonly used in Europe, have proven their excellent effectiveness-tolerability profile over decades in clinical practice and are therefore also highly recommended for the treatment of tics. Nevertheless, pharmacological treatment of tics remains an indiviual choice depending on each patient's own specific needs.

show abstract

Risperidone Treatment of Sleep Disturbances in Tourette’s Syndrome

Cited by 9 publications

References 11 publications

Tics bei Kindern und Jugendlichen

Tics bei Kindern und Jugendlichen

Tourette disorder and sleep

Update on the Pharmacological Treatment of Tics with Dopamine-Modulating Agents

Contact Info

Product

Resources

About